Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pieter Stolk

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Drug Safety|May 4, 2018
Challenges and Opportunities for the Traceability of (Biological) Medicinal ProductsKevin Klein, Pieter Stolk
Frontiers in Medicine|April 29, 2024
Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvalsKevin Klein, Jens Heisterberg, Pieter Stolk
Drug Safety|December 25, 2019
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UKKevin Klein, Lorna Hazell, Pieter Stolk, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 6, 2022
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 CountriesKevin Klein, Mümün Gencoglu, Jens Heisterberg, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory PathwaysLawrence Liberti, Neil McAuslane, Pieter Stolk, et al.
Drug Discovery Today|April 16, 2021
Regulatory density as a means to refine current regulatory approaches for increasingly complex medicinesKevin Klein, Pieter Stolk, Marie Louise De Bruin, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
Bulletin of the World Health Organization|November 28, 2006
Rare essentials: drugs for rare diseases as essential medicinesPieter Stolk, Marjolein J C Willemen, Hubert G M Leufkens
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 2, 2015
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance CentersKevin Klein, Marie L De Bruin, Andre W Broekmans, et al.
Frontiers in Medicine|July 19, 2021
The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines AgencyMarieke J H J Dekker, Pieter Stolk, Anna M G Pasmooij
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Drug Safety|May 4, 2018
Challenges and Opportunities for the Traceability of (Biological) Medicinal ProductsKevin Klein, Pieter Stolk
Frontiers in Medicine|April 29, 2024
Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvalsKevin Klein, Jens Heisterberg, Pieter Stolk
Drug Safety|December 25, 2019
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UKKevin Klein, Lorna Hazell, Pieter Stolk, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 6, 2022
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 CountriesKevin Klein, Mümün Gencoglu, Jens Heisterberg, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory PathwaysLawrence Liberti, Neil McAuslane, Pieter Stolk, et al.
Drug Discovery Today|April 16, 2021
Regulatory density as a means to refine current regulatory approaches for increasingly complex medicinesKevin Klein, Pieter Stolk, Marie Louise De Bruin, et al.
Drug Discovery Today|September 15, 2018
The future of drug development: the paradigm shift towards systems therapeuticsMeindert Danhof, Kevin Klein, Pieter Stolk, et al.
Bulletin of the World Health Organization|November 28, 2006
Rare essentials: drugs for rare diseases as essential medicinesPieter Stolk, Marjolein J C Willemen, Hubert G M Leufkens
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 2, 2015
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance CentersKevin Klein, Marie L De Bruin, Andre W Broekmans, et al.
Frontiers in Medicine|July 19, 2021
The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines AgencyMarieke J H J Dekker, Pieter Stolk, Anna M G Pasmooij
Pageof 4